We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Luminex Corp. has finally closed the acquisition of Nanosphere Inc for $1.70 per share on Jun 30. Notably, Nanosphere will function as a wholly ¬owned subsidiary of Luminex post the transaction.
The deal was initially announced by Luminex on May 16 at $1.35 per share, but later on May 22 the bid was increased by 35 cents per share.
Post completion of the acquisition, Luminex maintains its full-year 2016 revenue guidance range of $28 million to $30 million. The company also anticipates revenue contribution from Nanosphere in the band of $13 million to $16 million.
Nanosphere is a well known company in the healthcare economics space with a strong clientele engaged in the development of molecular diagnostic tools. The company offers a unified solution for sensitive genomic and protein testing by Verigene Technology, an important platform in the molecular diagnostic testing platform.
We believe the acquisition will now enable Luminex to utilize Nanosphere’s high-end protein testing technology and expand its customer base, especially in hospital-based laboratories and academic research institutions.
The diversified product portfolio that evolves post the acquisition will help Luminex combat industry challenges and drive penetration in the molecular microbiology and diagnostic markets.
In the global scenario, data from Markets and Markets reveal that the molecular diagnostics market is estimated to grow at a CAGR of 9.3% to reach $9,333.8 million by 2020. Such market trends can also prove accretive for Luminex, as its newly acquired company enjoys a dominant position in the field of molecular diagnostic testing.
Zacks Rank & Other Key Picks
Luminex carries a Zacks Rank #3 (Hold).
Other favorably ranked stocks in the broader medical sector include Masimo Corporation (MASI - Free Report) , Mesa Laboratories Inc (MLAB - Free Report) and CryoLife Inc . All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Luminex Closes Nanosphere Buyout, Maintains FY16 View
Luminex Corp. has finally closed the acquisition of Nanosphere Inc for $1.70 per share on Jun 30. Notably, Nanosphere will function as a wholly ¬owned subsidiary of Luminex post the transaction.
The deal was initially announced by Luminex on May 16 at $1.35 per share, but later on May 22 the bid was increased by 35 cents per share.
Post completion of the acquisition, Luminex maintains its full-year 2016 revenue guidance range of $28 million to $30 million. The company also anticipates revenue contribution from Nanosphere in the band of $13 million to $16 million.
Nanosphere is a well known company in the healthcare economics space with a strong clientele engaged in the development of molecular diagnostic tools. The company offers a unified solution for sensitive genomic and protein testing by Verigene Technology, an important platform in the molecular diagnostic testing platform.
LUMINEX CORP Price and Consensus
LUMINEX CORP Price and Consensus | LUMINEX CORP Quote
We believe the acquisition will now enable Luminex to utilize Nanosphere’s high-end protein testing technology and expand its customer base, especially in hospital-based laboratories and academic research institutions.
The diversified product portfolio that evolves post the acquisition will help Luminex combat industry challenges and drive penetration in the molecular microbiology and diagnostic markets.
In the global scenario, data from Markets and Markets reveal that the molecular diagnostics market is estimated to grow at a CAGR of 9.3% to reach $9,333.8 million by 2020. Such market trends can also prove accretive for Luminex, as its newly acquired company enjoys a dominant position in the field of molecular diagnostic testing.
Zacks Rank & Other Key Picks
Luminex carries a Zacks Rank #3 (Hold).
Other favorably ranked stocks in the broader medical sector include Masimo Corporation (MASI - Free Report) , Mesa Laboratories Inc (MLAB - Free Report) and CryoLife Inc . All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>